CBG (Cannabigerol)

 

Cannabigerol is one of the minor cannabinoids found in cannabis, typically most prevalent in high-CBD cultivars. This cannabinoid is newly discovered, but shows promise in fighting inflammation, pain, and nausea. CBG is the third most prevalent cannabinoid in cannabis.

Study cannabigerol

  • The Pharmacological Case for Cannabigerol

    Go to study

  • Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid

    Go to study

  • A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis

    Go to study

  • A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis

    Go to study

  • Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease

    Go to study

  • Synthesis and Antimicrobial Activities of Certain Cannabichromene and Cannabigerol Related Compounds

    Go to study

  • Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms

    Go to study

  • Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist

    Go to study